Author Archives: admin
Joint Venture Announced to Expand Use of Molecular Imaging in Ontario for Patient Care and Research of Cancer and Other Serious Diseases
CanProbe focuses on developing new radiopharmaceuticals to meet growing Canadian and global demand for advanced diagnostic and therapeutic molecular probes.
TORONTO, ON (June 22, 2011)-CanProbe, a unique, not-for-profit joint venture to advance the use of medical isotopes for diagnosing and treating cancer and other serious diseases, was announced today by the Centre for Probe Development and Commercialization (CPDC) and the University Health Network (UHN).
Non-reactor-based production of medical isotopes could provide Canadians with back-up or supplementary supplies and ease disruptions to patient scans.
Hamilton, ON (January 24, 2011) – The Centre for Probe Development and Commercialization (CPDC) joined the Government of Canada today to announce a national project to develop alternative sources of medical isotopes that could help to secure a reliable, long-term supply for Canadians.
A McMaster University professor, working on the next generation of molecular imaging probes for the early detection of disease, has been named one of Canada’s Top 40 Under 40.
TORONTO, ON (June 7, 2010) John Valliant, associate professor in the departments of Chemistry and Medical Physics, and CEO and scientific director of the Centre for Probe Development and Commercialization (CPDC), was included in the annual list of exceptional people, published in today’s edition of The Globe and Mail.
TORONTO, ON (June 19, 2009) Challenging times are shaping the future of molecular imaging probe development and nuclear medicine, according to the CPDC’s John Valliant. Valliant, PhD, scientific director and CEO at the CPDC, spoke at the Society of Nuclear Medicine’s Annual Meeting in Toronto on June 14, 2009, where he urged scientists to be innovative and not to rely on already established approaches and targets.